Work

Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.5_suppl.348

Authors: Robert A. Figlin, Asim Amin, Arkadiusz Dudek, Theodore Logan, Raymond S. Lance, Jeffrey M. Holzbeierlein, Viraj A. Master, Sumanta Kumar Pal, Alicia H. Gamble, Mark DeBenedette, Irina Y. Tcherepanova, W. Lee Williams, Doug Plessinger, Fred Miesowicz, Charles A. Nicolette, AGS-003-006 Study Group

Institutions: Cedars-Sinai Medical Center, City Of Hope National Medical Center, University of Minnesota, Emory University, Urology of Virginia, City of Hope, University of Kansas Medical Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2414352341

Cites:

Cited by: 22

Related to: 10